19613 GENES FOUNDi
Show / hide columns XML | RDF | TSV | « prev | Page of 393 | next »
Genei Gene descriptioni x Protein classi x Tissue Cell Pathology Subcellular locationi x Prognostic p-valuei x RNA tissue categoryi x
ADGRG2Adhesion G protein-coupled receptor G2Disease related genes
G-protein coupled receptors
Plasma proteins
Potential drug targets
Predicted membrane proteins
Plasma membrane
Cytosol
Tissue enriched
ADGRG3Adhesion G protein-coupled receptor G3G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Group enriched
ADGRG4Adhesion G protein-coupled receptor G4G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Tissue enhanced
ADGRG5Adhesion G protein-coupled receptor G5G-protein coupled receptors
Predicted membrane proteins
Predicted secreted proteins
Nucleoplasm
Nuclear membrane
Vesicles
Cervical cancer: 4.25e-4
Tissue enhanced
ADGRG6Adhesion G protein-coupled receptor G6Disease related genes
G-protein coupled receptors
Plasma proteins
Potential drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Pancreatic cancer: 2.78e-5
Lung cancer: 8.78e-4
Tissue enhanced
ADGRG7Adhesion G protein-coupled receptor G7G-protein coupled receptors
Predicted membrane proteins
Group enriched
ADGRL1Adhesion G protein-coupled receptor L1G-protein coupled receptors
Predicted intracellular proteins
Predicted membrane proteins
Pancreatic cancer: 1.14e-4
Renal cancer: 4.45e-4
Tissue enhanced
ADGRL2Adhesion G protein-coupled receptor L2G-protein coupled receptors
Predicted membrane proteins
Plasma membrane
Cell Junctions
Endometrial cancer: 1.33e-4
Stomach cancer: 3.00e-4
Liver cancer: 9.92e-4
Mixed
ADGRL3Adhesion G protein-coupled receptor L3G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Tissue enhanced
ADGRL4Adhesion G protein-coupled receptor L4G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Transporters
Renal cancer: 1.60e-4
Mixed
ADGRV1Adhesion G protein-coupled receptor V1Disease related genes
G-protein coupled receptors
Potential drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Transporters
Lipid dropletsTissue enriched
ADH1AAlcohol dehydrogenase 1A (class I), alpha polypeptideEnzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Plasma membrane
Cytosol
Liver cancer: 2.38e-4
Tissue enriched
ADH1BAlcohol dehydrogenase 1B (class I), beta polypeptideEnzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Plasma membrane
Cytosol
Renal cancer: 7.87e-4
Group enriched
ADH1CAlcohol dehydrogenase 1C (class I), gamma polypeptideEnzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Plasma membrane
Cytosol
Lung cancer: 2.99e-4
Liver cancer: 4.55e-4
Tissue enhanced
ADH4Alcohol dehydrogenase 4 (class II), pi polypeptideEnzymes
Plasma proteins
Predicted intracellular proteins
Nucleus
Cytosol
Liver cancer: 7.08e-6
Tissue enriched
ADH5Alcohol dehydrogenase 5 (class III), chi polypeptideEnzymes
Plasma proteins
Predicted intracellular proteins
Renal cancer: 4.58e-10
Endometrial cancer: 9.90e-5
Melanoma: 3.54e-4
Expressed in all
ADH6Alcohol dehydrogenase 6 (class V)Enzymes
Predicted intracellular proteins
Tissue enriched
ADH7Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptideEnzymes
Predicted intracellular proteins
Plasma membrane
Cytosol
Tissue enriched
ADHFE1Alcohol dehydrogenase, iron containing 1Enzymes
Predicted intracellular proteins
VesiclesRenal cancer: 4.55e-5
Breast cancer: 5.76e-5
Liver cancer: 9.90e-5
Mixed
ADI1Acireductone dioxygenase 1Enzymes
Predicted intracellular proteins
Predicted secreted proteins
Nucleoplasm
Golgi apparatus
Expressed in all
ADIGAdipogeninPredicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Group enriched
ADIPOQAdiponectin, C1Q and collagen domain containingCandidate cardiovascular disease genes
Disease related genes
Plasma proteins
Predicted secreted proteins
Tissue enriched
ADIPOR1Adiponectin receptor 1Predicted intracellular proteins
Predicted membrane proteins
Transporters
Ovarian cancer: 5.27e-4
Pancreatic cancer: 5.50e-4
Expressed in all
ADIPOR2Adiponectin receptor 2Predicted membrane proteins
Expressed in all
ADIRFAdipogenesis regulatory factorPlasma proteins
Predicted intracellular proteins
Nucleoplasm
Cytosol
Tissue enhanced
ADKAdenosine kinaseDisease related genes
Enzymes
FDA approved drug targets
Predicted intracellular proteins
Nucleoplasm
Cytosol
Head and neck cancer: 1.93e-4
Liver cancer: 9.91e-4
Expressed in all
ADMAdrenomedullinCancer-related genes
Plasma proteins
Predicted intracellular proteins
Predicted secreted proteins
Renal cancer: 6.33e-4
Liver cancer: 7.56e-4
Expressed in all
ADM2Adrenomedullin 2Predicted secreted proteins
Thyroid cancer: 2.72e-4
Tissue enhanced
ADM5Adrenomedullin 5 (putative)Predicted secreted proteins
Urothelial cancer: 6.74e-4
Mixed
ADNPActivity dependent neuroprotector homeoboxCancer-related genes
Disease related genes
Predicted intracellular proteins
Transcription factors
NucleoplasmLiver cancer: 1.65e-5
Expressed in all
ADNP2ADNP homeobox 2Predicted intracellular proteins
Transcription factors
Mitochondria
Cytosol
Renal cancer: 6.39e-5
Thyroid cancer: 9.90e-4
Mixed
ADO2-aminoethanethiol dioxygenaseEnzymes
Predicted intracellular proteins
Liver cancer: 8.01e-5
Expressed in all
ADORA1Adenosine A1 receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Plasma membraneTissue enhanced
ADORA2AAdenosine A2a receptorCancer-related genes
FDA approved drug targets
G-protein coupled receptors
Predicted intracellular proteins
Predicted membrane proteins
Transporters
Tissue enhanced
ADORA2BAdenosine A2b receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
CytosolMixed
ADORA3Adenosine A3 receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Mixed
ADPGKADP dependent glucokinaseEnzymes
Predicted intracellular proteins
Predicted secreted proteins
CentrosomeRenal cancer: 4.52e-7
Prostate cancer: 2.22e-4
Mixed
ADPRHADP-ribosylarginine hydrolaseEnzymes
Predicted intracellular proteins
Nucleus
Nuclear membrane
Breast cancer: 2.42e-4
Mixed
ADPRHL1ADP-ribosylhydrolase like 1Predicted intracellular proteins
NucleoplasmLiver cancer: 2.55e-5
Head and neck cancer: 4.88e-4
Group enriched
ADPRHL2ADP-ribosylhydrolase like 2Enzymes
Predicted secreted proteins
NucleoplasmLiver cancer: 2.10e-7
Renal cancer: 3.71e-4
Expressed in all
ADPRMADP-ribose/CDP-alcohol diphosphatase, manganese dependentEnzymes
Predicted intracellular proteins
Predicted membrane proteins
Endometrial cancer: 2.38e-5
Cervical cancer: 1.69e-4
Expressed in all
ADRA1AAdrenoceptor alpha 1AFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Tissue enhanced
ADRA1BAdrenoceptor alpha 1BCancer-related genes
FDA approved drug targets
G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Plasma membraneRenal cancer: 1.40e-6
Thyroid cancer: 3.19e-5
Endometrial cancer: 6.00e-5
Ovarian cancer: 2.67e-4
Glioma: 6.07e-4
Tissue enhanced
ADRA1DAdrenoceptor alpha 1DFDA approved drug targets
G-protein coupled receptors
Plasma proteins
Predicted membrane proteins
Tissue enhanced
ADRA2AAdrenoceptor alpha 2AFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Endometrial cancer: 8.06e-4
Mixed
ADRA2BAdrenoceptor alpha 2BPredicted membrane proteins
Mixed
ADRA2CAdrenoceptor alpha 2CFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Tissue enhanced
ADRB1Adrenoceptor beta 1FDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enhanced
ADRB2Adrenoceptor beta 2FDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
CytosolRenal cancer: 3.15e-9
Mixed
ADRB3Adrenoceptor beta 3FDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Tissue enhanced
« prev | Page of 393 | next »